Alnylam Pharmaceuticals announced a $250 million investment to install a proprietary siRELIS™ enzymatic‑ligation platform at its Norton, Massachusetts manufacturing site. The new plant will be the first fully dedicated, proprietary siRNA enzymatic‑ligation facility in the industry, and it has already received FDA acceptance into the Emerging Technology Program, giving the company a regulatory advantage for future RNAi products.
The expansion is designed to increase throughput and lower per‑dose manufacturing costs, enabling Alnylam to meet the rising global demand for its RNAi therapeutics. By adding the siRELIS™ platform, the company can produce larger volumes of siRNA molecules more efficiently, using fewer raw materials and less plant space. This capability will support the launch of new pipeline candidates—including those targeting hypertension, type 2 diabetes, and obesity—while sustaining the strong sales momentum of its flagship ATTR‑amyloidosis therapy, AMVUTTRA.
Alnylam’s Q3 2025 results underscore the strategic value of the expansion. Total net product revenues rose to $851 million, a 103 % year‑over‑year increase, and earnings per share of $2.90 beat analyst expectations of $1.23 by $1.67. The company’s commercial sales of AMVUTTRA reached $685 million, up 135 % YoY, reflecting robust market penetration and pricing power. The strong financial performance, combined with the new manufacturing capacity, positions Alnylam to capture additional market share and accelerate product launches.
CEO Yvonne Greenstreet said the investment “accelerates development of siRNA manufacturing and changes what’s possible in a single facility.” Chief Technical Operations and Quality Officer Timothy Maines added that the siRELIS™ platform “increases throughput while maintaining the highest quality standards,” highlighting the company’s focus on operational excellence and cost control.
The expansion strengthens Alnylam’s competitive position in the RNAi market, where manufacturing complexity is a key barrier to entry. By securing FDA approval for its new platform and expanding capacity ahead of future product launches, Alnylam is poised to sustain its growth trajectory and reinforce its strategy to become a scalable, profitable platform company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.